Fedratinib
- Generic Name
- Fedratinib
- Brand Names
- Inrebic
- Drug Type
- Small Molecule
- Chemical Formula
- C27H36N6O3S
- CAS Number
- 936091-26-8
- Unique Ingredient Identifier
- 6L1XP550I6
- Background
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis. It is an anilinopyrimidine derivative.
Fedratinib was granted FDA approval on August 16, 2019.
- Indication
Fedratinib is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
- Associated Conditions
- Secondary Myelofibrosis, Primary Myelofibrosis (PMF)
- Associated Therapies
- -
Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 32
- Registration Number
- NCT03983239
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc - Dallas, Dallas, Texas, United States
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
- Conditions
- Interventions
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 202
- Registration Number
- NCT03952039
- Locations
- 🇦🇹
Local Institution - 153, Wels, Austria
🇦🇹Local Institution - 155, Linz, Austria
🇦🇹Local Institution - 151, Salzburg, Austria
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 38
- Registration Number
- NCT03755518
- Locations
- 🇺🇸
Local Institution - 123, Baltimore, Maryland, United States
🇨🇦Local Institution - 200, Toronto, Ontario, Canada
🇺🇸Local Institution - 112, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.